The expression of complement regulatory proteins by adult human oligodendrocytes

Journal of Neuroimmunology

Volumn 84, Issue 1, 1998, Pages 69-75

  Scolding, N J ^a,b   Morgan, B P ^c   Compston, D A S ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

CD59; Demyelinating disease; Glia

Indexed keywords

CD59 ANTIGEN; COMPLEMENT; MONOCYTE CHEMOTACTIC PROTEIN 1; REGULATOR PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; BRAIN PROTECTION; DEMYELINATION; HOST RESISTANCE; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; LYMPHOCYTIC INFILTRATION; MULTIPLE SCLEROSIS; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS REGULATION; T LYMPHOCYTE ACTIVATION;

ANTIGENS, CD59; CELLS, CULTURED; CLUSTERIN; COMPLEMENT INACTIVATOR PROTEINS; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT SYSTEM PROTEINS; DEMYELINATING DISEASES; GLYCOPROTEINS; HUMANS; MOLECULAR CHAPERONES; MULTIPLE SCLEROSIS; OLIGODENDROGLIA;

EID: 0032053601     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(97)00241-5     Document Type: Article

References (53)

1. Armstrong R.C., Dorn H.H., Kufta C.V., Friedman E., DuboisDalcq M.E. Pre-oligodendrocytes from adult human CNS. J. Neurosci. 12:1992;1538-1547.
2. Asghar S.S. Membrane regulators of complement activation and their aberrant expression in disease. Lab. Invest. 72:1995;254-271.
3. Barnum S.R. Complement biosynthesis in the central nervous system. Crit. Rev. Oral Biol. Med. 6:1995;132-146.
4. Bellander B.M., Von Holst H., Fredman P., Svensson M. Activation of the complement cascade and increase of clusterin in the brain following a cortical contusion in the adult rat. J. Neurosurg. 85:1996;468-475.
5. Bottenstein J.E., Sato G.H. Growth of a rat neuroblastoma line in serum free supplemented medium. Proc. Natl. Acad. Sci. U.S.A. 76:1979;514-517.
6. Compston D.A.S., Morgan B.P., Campbell A.K., Wilkins P., Cole G., Thomas N.D., Jasani B. Immunocytochemical localization of the terminal complement complex in multiple sclerosis. Neuropathol. Appl. Neurobiol. 15:1989;307-316.
7. Funabashi K., Okada N., Matsuo S., Yamamoto T., Morgan B.P., Okada H. Tissue distribution of complement regulatory membrane proteins in rats. Immunology. 81:1994;444-451.
8. Gasque P., Morgan B.P. Complement regulatory protein expression by a human oligodendrocyte cell line: cytokine regulation and comparison with astrocytes. Immunology. 89:1996;338-347.
9. Gasque P., Fontaine M., Morgan B.P. Complement expression in human brain: biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. J. Immunol. 154:1995;4726-4733.
10. Gordon D.L., Papazaharoudakis H., Sadlon T.A., Arellano A., Okada N. Upregulation of human neutrophil CD59, a regulator of the membrane attack complex of complement, following cell activation. Immunol. Cell Biol. 72:1994;222-229.
11. Hildebrand C., Remahl S., Persson H., Bjartmar C. Myelinated nerve fibres in the CNS. Prog. Neurobiol. 40:1993;319-384.
12. Koski C.L., Estep A.E., SawantMane S., Shin M.L., Highbarger L., Hansch G.M. Complement regulatory molecules on human myelin and glial cells: differential expression affects the deposition of activated complement proteins. J. Neurochem. 66:1996;303-312.
13. Kumar S., Vinci J.M., Pytel B.A., Baglioni C. Expression of messenger RNAs for complement inhibitors in human tissues and tumors. Cancer Res. 53:1993;348-353.
14. Lindsberg P.J., Ohman J., Lehto T., KarjalainenLindsberg M.L., Pactau A., Wuorimaa T., Carpen O., Kaste M., Meri S. Complement activation in the central nervous system following blood-brain barrier damage in man. Ann. Neurol. 40:1996;587-596.
15. Liu C.C., Walsh C.M., Young J.D.E. Perforin: structure and function. Immunol. Today. 16:1995;194-201.
16. May P.C., Finch C.E. Sulfated glycoprotein: II. New relationships of this multifunctional protein to neurodegeneration. Trends Neurosci. 15:1992;391-396.
17. McGeer P.L., McGeer E.G. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Rev. 21:1995;195-218.
18. Meri S., Morgan B.P., Davies A., Daniels R.H., Olavesen M.G., Waldmann H., Lachmann P.J. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology. 71:1990;1-9.
19. Meri S., Waldmann H., Lachmann P.J. Distribution of protectin-(CD59), a complement membrane attack inhibitor, in normal human tissues. Lab. Invest. 65:1991;532-537.
20. Morgan B.P. Physiology and pathophysiology of complement: progress and trends. Crit. Rev. Clin. Lab. Sci. 32:1995;265-298.
21. Morgan B.P., Meri S. Membrane proteins that protect against complement lysis. Springer Semin. Immunopathol. 15:1994;369-396.
22. Morgan B.P., Gasque P. Expression of complement in the brain: role in health and disease. Immunol. Today. 17:1996;461-466.
23. Nose M., Katoh M., Okada N., Kyogoku M., Okada H. Tissue distribution of HRF20, a novel factor preventing the membrane attack of homologous complement, and its predominant expression on endothelial cells in vivo. Immunology. 70:1990;145-149.
24. Olsson T. Immunology of multiple sclerosis. Curr. Opin. Neurol. Neurosurg. 5:1992;195-202.
25. Pasinetti G.M., Johnson S.A., Oda T., Rozovsky I., Finch C.E. Clusterin (SGP-2): a multifunctional glycoprotein with regional expression in astrocytes and neurons of the adult rat brain. J. Comp. Neurol. 339:1994;387-400.
26. Piddlesden S.J., Morgan B.P. Killing of rat glial cells by complement: deficiency of the rat analogue of CD59 is the cause of oligodendrocyte susceptibility to lysis. J. Neuroimmunol. 48:1993;169-176.
27. Piddlesden S.J., Storch M.K., Hibbs M., Freeman A.M., Lassmann H., Morgan B.P. Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J. Immunol. 152:1994;5477-5484.
28. RioHortega P. Tercera aportacia al conocimiento morfologico e interpretacion funcional de la oligodendroglia. Mem. Real Soc. Exp. Hist. Nat. 14:1928;5-122.
29. Roddy J., Clark I., Hazleman B.L., Compston D.A.S., Scolding N.J. Cerebrospinal fluid concentrations of the complement MAC inhibitor CD59 in multiple sclerosis and patients with other neurological disorders. J. Neurol. 241:1994;557-560.
30. Rogers C.A., Gasque P., Piddlesden S.J., Okada N., Holers V.M., Morgan B.P. Expression and function of membrane regulators of complement on rat astrocytes in culture. Immunology. 88:1996;153-161.
31. Rosenberg M.E., Silkensen J. Clusterin: physiologic and pathophysiologic considerations. Int. J. Biochem. Cell Biol. 27:1995;633-645.
32. Rosse W.F. Phosphatidylinositol-linked proteins and paroxysmal nocturnal haemoglobinuria. Blood. 75:1990;1595-1601.
33. Ruijs T.C.G., Olivier A., Antel J.P. Serum cytotoxicity to human and rat oligodendrocytes in culture. Brain Res. 517:1990;99-104.
34. Rus H.G., Niculescu F., Shin M.L. Sublytic complement attack induces cell cycle in oligodendrocytes: S phase induction is dependent on c-jun activation. J. Immunol. 156:1996;4892-4900.
35. Sanders M.E., Koski C.L., Robbins D.et al. Activated terminal complement in cerebrospinal fluid in Guillain-Barre syndrome and multiple sclerosis. J. Immunol. 136:1986;4456-4459.
36. Scolding N.J., Houston W.A.J., Morgan B.P., Campbell A.K., Compston D.A.S. Reversible injury of cultured rat oligodendrocytes by complement. Immunology. 67:1989;441-446.
37. Scolding N.J., Morgan B.P., Houston W.A.J., Linington C., Campbell A.K., Compston D.A.S. Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement. Nature. 339:1989;620-622.
38. Scolding N.J., Morgan B.P., Houston A., Campbell A.K., Linington C., Compston D.A.S. Normal rat serum cytotoxicity, against syngeneic oligodendrocytes. Complement activation and attack in the absence of anti-myelin antibodies. J. Neurol. Sci. 89:1989;289-300.
39. Scolding N.J., Zajicek J.P., Wood N., Compston D.A.S. The pathogenesis of demyelinating disease. Prog. Neurobiol. 43:1994;143-173.
40. Scolding N.J., Rayner P.J., Sussman J., Shaw C., Compston D.A.S. A proliferative adult human oligodendrocyte progenitor. NeuroReport. 6:1995;441-445.
41. Shirazi Y., Imagawa D.K., Shin M.L. Release of leukotriene B4 from sublethally injured oligodendrocytes by terminal complement complexes. J. Neurochem. 48:1987;271-278.
42. Shirazi Y., McMorris F.A., Shin M.L. Arachidonic acid mobilization and phosphoinositide turnover by the terminal complement complex, C5b-9, in rat oligodendrocyte×C6 glioma cell hybrids. J. Immunol. 142:1989;4385-4391.
43. Shirazi Y., Rus H.G., Macklin W.B., Shin M.L. Enhanced degradation of messenger RNA encoding myelin proteins by terminal complement complexes in oligodendrocytes. J. Immunol. 150:1993;4581-4590.
44. Singhrao S.K., Neal J.W., Gasque P., Morgan B.P., Newman G.R. Role of complement in the aetiology of Pick's disease? J. Neuropathol. Exp. Neurol. 55:1996;578-593.
45. Tandon N., Yan S.L., Morgan B.P., Weetman A.P. Expression and function of multiple regulators of complement activation in autoimmune thyroid disease. Immunology. 81:1994;643-647.
46. Tschopp J., French L.E. Clusterin: modulation of complement function. Clin. Exp. Immunol. 97:1994;11-14.
47. Vedeler C., Ulvestad E., Bjorge L., Conti G., Williams K., Mork S., Matre X.X. The expression of CD59 in normal human nervous tissue. Immunology. 82:1994;542-547.
48. Venneker G.T., Van den Hoogen F.H.J., Boerbooms A.M.T., Bos J.D., Asghar S.S. Aberrant expression of membrane cofactor protein and decay-accelerating factor in the endothelium of patients with systemic sclerosis: A possible mechanism of vascular damage. Lab. Invest. 70:1994;830-835.
49. Wing M.G., Zajicek J., Seilly D.J., Compston D.A.S., Lachmann P.J. Oligodendrocytes lack glycolipid anchored proteins which protect them against complement lysis. Restoration of resistance to lysis by incorporation of CD59. Immunology. 76:1992;140-145.
50. Wu E., Brosnan C.F., Raine C.S. SP-40,40 immunoreactivity in inflammatory CNS lesions displaying astrocyte/oligodendrocyte interactions. J. Neuropathol. Exp. Neurol. 52:1993;129-134.
51. Zajicek J., Wing M.G., Lachmann P.J., Compston D.A.S. Mechanisms of oligodendrocyte interaction with normal human serum: defining the role of complement. J. Neurol. Sci. 108:1992;65-72.
52. Zajicek J., Wing M.G., Scolding N.J., Lachmann P.J., Compston D.A.S. Interactions between oligodendrocytes and microglia. Brain. 115:1992;1611-1632.
53. Zajicek J., Wing M., Skepper J., Compston A. Human oligodendrocytes are not sensitive to complement: a study of CD59 expression in the human central nervous system. Lab. Invest. 73:1995;128-138.